<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04691141</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-016-MDS-001</org_study_id>
    <nct_id>NCT04691141</nct_id>
  </id_info>
  <brief_title>A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS)</brief_title>
  <acronym>HATCH</acronym>
  <official_title>A Phase I/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) Patients After Failure of Hypomethylating Agent (HMA)-Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Antengene Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and&#xD;
      Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome&#xD;
      (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ⅰ/II, Open-label Study to Investigate the Pharmacokinetics, Safety, and&#xD;
      Efficacyof ATG 016 Monotherapy in IPSS-R Intermediate Risk and above Myelodysplastic Syndrome&#xD;
      (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy. In Phase I:&#xD;
      approximately 15 to 21 subjects and Phase II: approximately 44 subjects; approximately 59 to&#xD;
      65 subjects will be enrolled totally in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2021</start_date>
  <completion_date type="Anticipated">March 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD in Phase I</measure>
    <time_frame>16 months</time_frame>
    <description>MTD will be evaluated using the NCI-CTCAE, Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D in Phase I</measure>
    <time_frame>16 months</time_frame>
    <description>RP2D will be determined under the guidance of the SRC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AEs/SAEs</measure>
    <time_frame>25 months</time_frame>
    <description>Toxicity will be graded according to the NCI CTCAE, Version 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR in Phase II</measure>
    <time_frame>25 months</time_frame>
    <description>Based on 2006 IWG Response Criteria, evaluated by IRC: ORR (CR + PR + mCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in Phase I/II</measure>
    <time_frame>12 months</time_frame>
    <description>DCR (CR + PR + mCR + HI + SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) in Phase I/II</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in Phase I/II</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>12 months</time_frame>
    <description>The estimates of Kaplan-Meier</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ATG-016</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg QD×Days 1-5/week will be the initial dose of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-016</intervention_name>
    <description>59 patients enrolled will be treated with 5 mg (QD×Days 1-5/week), orally, each 4 week (28-day) a cycle</description>
    <arm_group_label>ATG-016</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand and voluntarily sign an informed consent document prior to any study&#xD;
             related assessments/procedures are conducted.&#xD;
&#xD;
          2. ≥18 years of age, males or females.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.&#xD;
&#xD;
          4. A life expectancy longer than 3 months in the opinion of the investigator at the&#xD;
             screening.&#xD;
&#xD;
          5. Male subjects (Including those who have received vasectomy) must agree to use condoms&#xD;
             during sex with a woman of childbearing age and have no plans to impregnate the woman&#xD;
             throughout the study and for 3 months following the last dose after the date of&#xD;
             signing the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of central nervous system (CNS) involvement.&#xD;
&#xD;
          2. Toxicity from prior antitumor therapy did not return to Grade 1 or baseline (Except&#xD;
             for alopecia, neutropenia, anemia, and thrombocytopenia. For neutrophils, hemoglobin,&#xD;
             and platelets, please follow Exclusion Criteria No. 5).&#xD;
&#xD;
          3. History of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          4. History of severe bleeding disorder, such as hemophilia A, hemophilia B, and vascular&#xD;
             hemophilia.&#xD;
&#xD;
          5. History of allogeneic stem-cell transplantation.&#xD;
&#xD;
          6. Serious psychiatric or medical conditions that, in the opinion of the investigator,&#xD;
             could interfere with treatment, compliance, or the ability to give consent.&#xD;
&#xD;
          7. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhijian Xiao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin blood research institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimin Sun, MD</last_name>
    <phone>13701803117</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaobei He, MD</last_name>
    <phone>13916910751</phone>
    <email>xiaobei.he@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Du, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Xin Du, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin blood research institute</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhijian Xiao, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Zhijian Xiao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

